1. Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation

   • Scott D. Nelson
   • Daniel Malone
   • Joanne Lafleur

   Practical Application 06 May 2015 Pages: 887 - 892

   

2. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective

   • Nigel Fleeman
   • Adrian Bagust
   • Lindsay Banks

   Review Article 24 April 2015 Pages: 893 - 904

   

3. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

   • Bonny Parkinson
   • Catherine Sermet
   • Adam G. Elshaug

   Review Article 06 June 2015 Pages: 905 - 924

   

4. The Economic and Humanistic Burden of Severe Sepsis

   • Bogdan Tiru
   • Ernest K. DiNino
   • William T. McGee

   Review Article 03 May 2015 Pages: 925 - 937

   

5. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review

   • Yoko V. Laurence
   • Ulla K. Griffiths
   • Anna Vassall

   Systematic Review Open access 05 May 2015 Pages: 939 - 955

   

6. Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia

   • Sabina Sanghera
   • Emma Frew
   • Tracy Elizabeth Roberts

   Original Research Article Open access 25 April 2015 Pages: 957 - 965

   

7. A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark

   • Anne Sig Vestergaard
   • Lars Holger Ehlers

   Original Research Article 06 May 2015 Pages: 967 - 979

   

8. Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”

   • Afschin Gandjour

   Letter to the Editor 30 July 2015 Pages: 981 - 982

9. The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”

   • Janneke P. C. Grutters
   • Marjolein B. A. van Asselt
   • Manuela A. Joore

   Letter to the Editor 28 August 2015 Pages: 983 - 983